Pirtobrutinib
Non-covalent (reversible) BTK inhibitor
- Response rate
- ~68% ORR (after covalent BTKi); 56% VGPR with venetoclax combo
- Onset
- Weeks
- Route
- Oral 200mg daily
- Line
- 2nd
- IgM effect
- Reduction
Evidence summary
Non-covalent BTK inhibitor that retains activity after covalent BTK inhibitor resistance or intolerance. Being studied in combination with venetoclax (pirtobrutinib + venetoclax: 100% ORR, 56% VGPR in interim analysis). May overcome acquired BTK C481S resistance mutations.
Molecular targets (1)
| Molecule | Role | Expression | Evidence |
|---|---|---|---|
| BTK (Bruton's Tyrosine Kinase) | Key signaling kinase downstream of MYD88 | Constitutively activated | established |